Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tunlametinib Plus Docetaxel in KRAS Mutant NSCLC
NCT03990077Phase 1Terminated
- Sponsor
- Shanghai KeChow Pharmaceuticals
- Start
- May 2020
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tunlametinib in non-small cell lung cancer (NSCLC), sponsored by Shanghai KeChow Pharmaceuticals. Primary endpoints: Number of Adverse Events at 24 months and Maximum Tolerated Dose at 35 days. Started May 2020; status: terminated.
02
Drugs
tunlametinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03990077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03990077.